Results 21 to 30 of about 11,227 (157)

Micafungin: A New Echinocandin [PDF]

Clinical Infectious Diseases, 2006
Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
P H, Chandrasekar, J D, Sobel
openaire   +2 more sources

Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children

Journal of Fungi, 2023
During the past decade, Candida auris emerged across the world, causing nosocomial outbreaks in both pediatric and adult populations, particularly in intensive care settings.
Liat Ashkenazi-Hoffnung, Chen Rosenberg Danziger   +1 more
doaj   +1 more source

Gel Formulations with an Echinocandin for Cutaneous Candidiasis: The Influence of Azone and Transcutol on Biopharmaceutical Features

Gels, 2023
Caspofungin is a drug that is used for fungal infections that are difficult to treat, including invasive aspergillosis and candidemia, as well as other forms of invasive candidiasis.
Noelia Pérez-González, Lupe Carolina Espinoza, María Rincón, Lilian Sosa, Mireia Mallandrich, Joaquim Suñer-Carbó, Nuria Bozal-de Febrer, Ana Cristina Calpena, Beatriz Clares-Naveros   +8 more
doaj   +1 more source

Functional redundancy in Echinocandin B in-cluster transcription factor ecdB of Emericella rugulosa NRRL 11440

Biotechnology Reports, 2018
Echinocandin B is a potent antifungal against the majority of fungal pathogens and its biosynthesis occurred by ecd and hty gene clusters in Emericella rugulosa NRRL 11440. We elucidated the functional necessity of in-clustered transcription factor; ecdB
Arvind Kumar, Varun Jaiswal, Vinay Kumar, Amitava Dey, Antresh Kumar   +4 more
doaj   +1 more source

Functional Genomic Screening Reveals Core Modulators of Echinocandin Stress Responses in Candida albicans

Cell Reports, 2018
Summary: Candida albicans is a leading cause of death due to fungal infection. Treatment of systemic candidiasis often relies on echinocandins, which disrupt cell wall synthesis. Resistance is readily acquired via mutations in the drug target gene, FKS1.
Tavia Caplan, Elizabeth J. Polvi, Jinglin L. Xie, Shoshana Buckhalter, Michelle D. Leach, Nicole Robbins, Leah E. Cowen   +6 more
doaj   +1 more source

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data

Journal of Fungi, 2020
Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique ...
Yanan Zhao, David S. Perlin
doaj   +1 more source

An Alanine Aminotransferase Is Required for Biofilm-Specific Resistance of Aspergillus fumigatus to Echinocandin Treatment

mBio, 2022
Alanine metabolism has been suggested as an adaptation strategy to oxygen limitation in organisms ranging from plants to mammals. Within the pulmonary infection microenvironment, Aspergillus fumigatus forms biofilms with steep oxygen gradients defined by
Joshua D. Kerkaert, François Le Mauff, Benjamin R. Wucher, Sarah R. Beattie, Elisa M. Vesely, Donald C. Sheppard, Carey D. Nadell, Robert A. Cramer   +7 more
doaj   +1 more source

Echinocandins in antifungal pharmacotherapy [PDF]

Journal of Pharmacy and Pharmacology, 2017
Abstract Objectives Echinocandins are the newest addition of the last decade to the antifungal armamentarium, which, owing to their unique mechanism of action, selectively target the fungal cells without affecting mammalian cells.
Akash Patil, Soumyajit Majumdar
openaire   +2 more sources

New Horizons in Antifungal Therapy

Journal of Fungi, 2016
Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics.
Kaila M. Pianalto, J. Andrew Alspaugh
doaj   +1 more source

Echinocandins in invasive candidiasis

Mycoses, 2013
SummaryWe summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managingIC. The echinocandins have demonstrated good activity against non‐albicansinfections and also azole‐resistant strains, both preclinically and in recent clinical trials.
Simon, J., Sun, H.-Y., Leong, H.N., Barez, M.Y.C., Huang, P.-Y., Talwar, D., Wang, J.-H., Mansor, M., Wahjuprajitno, B., Patel, A., Wittayachanyapong, S., Sany, B.S.M., Lin, S.-F., Dimopoulos, G.   +13 more
openaire   +3 more sources